<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05030376</url>
  </required_header>
  <id_info>
    <org_study_id>QLYY-CRC-2020-001</org_study_id>
    <nct_id>NCT05030376</nct_id>
  </id_info>
  <brief_title>Intraileal Glucose vs. Saline Infusion on Hormone Secretion and Glycemic Excursions</brief_title>
  <official_title>Comparative Effects of Intraileal Glucose vs. Saline Infusion on Hormone Secretion and Glycemic Excursions in Subjects With Ileostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Shandong First Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The distal ileum, where the glucagon-like peptide 1 (GLP-1) releasing cells predominate, is&#xD;
      an important organ in mediating glycemic control. However, the distal ileum is not easy to&#xD;
      access and the correspond in vivo research remains to be difficult. The investigators intend&#xD;
      to recruit subjects who underwent rectal surgery with simultaneous protective ileostomy and&#xD;
      evaluate hormone secretion and glycemic excursions via ileostomy glucose or saline infusion,&#xD;
      and quantify the glucose absorption rate within the distal ileum.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum or plasma GLP-1 changes during intraileal infusion</measure>
    <time_frame>180 minutes</time_frame>
    <description>concentration of serum or plasma GLP-1 (pmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum or plasma GIP changes during intraileal infusion</measure>
    <time_frame>180 minutes</time_frame>
    <description>concentration of serum or plasma GIP (pmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum or plasma ghrelin changes during intraileal infusion</measure>
    <time_frame>180 minutes</time_frame>
    <description>concentration of serum or plasma ghrelin (pg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum or plasma c-peptide changes during intraileal infusion</measure>
    <time_frame>180 minutes</time_frame>
    <description>concentration of serum or plasma c-peptide (pmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum or plasma insulin changes during intraileal infusion</measure>
    <time_frame>180 minutes</time_frame>
    <description>concentration of serum or plasma insulin (pmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum or plasma glucagon changes during intraileal infusion</measure>
    <time_frame>180 minutes</time_frame>
    <description>concentration of serum or plasma glucagon (pmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>glucose absorption capacity</measure>
    <time_frame>180 minutes</time_frame>
    <description>estimated glucose absorption rate during intraileal glucose infusion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Incretins</condition>
  <arm_group>
    <arm_group_label>patients with ileostomy without type 2 diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intraileal glucose or saline infusion via ileostomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with ileostomy with type 2 diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intraileal glucose or saline infusion via ileostomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>intraileal infusion</intervention_name>
    <description>intraileal glucose or intraileal saline infusion</description>
    <arm_group_label>patients with ileostomy with type 2 diabetes</arm_group_label>
    <arm_group_label>patients with ileostomy without type 2 diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and postmenopausal females aged 18 - 75 years&#xD;
&#xD;
          -  Body mass index (BMI) 20 - 35 kg/m2&#xD;
&#xD;
          -  With protective ileostomy due to benign or malignant rectal surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of postoperative adjuvant chemotherapy&#xD;
&#xD;
          -  Other significant illness, including epilepsy, cardiovascular or respiratory disease&#xD;
&#xD;
          -  Impaired renal or liver function (as assessed by calculated creatinine clearance &lt; 90&#xD;
             mL/min or abnormal liver function tests (&gt; 2 times upper limit of normal range))&#xD;
&#xD;
          -  Donation of blood within the previous 3 months&#xD;
&#xD;
          -  Participation in any other research studies within the previous 3 months&#xD;
&#xD;
          -  Females who are pre-menopausal&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Vegetarians&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kexin Wang</last_name>
    <role>Study Director</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Zhang</last_name>
      <phone>18560089182</phone>
      <email>xiang.zhang02@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhiqiang Cheng</last_name>
      <phone>18560085238</phone>
      <email>hill988276@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>the first affiliated hospital of Shandong First Medical University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wenjie Zhang</last_name>
      <phone>18366118551</phone>
      <email>727778132@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital of Shandong University</investigator_affiliation>
    <investigator_full_name>Sanyuan Hu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

